C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral, potent and ...

CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

- Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for ...

The Key Complement 3 Glomerulopathy Companies in the market include - NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others. DelveInsight’s “Complement 3 ...

An ultra-rare kidney disease that can become life-threatening now has its first FDA-approved therapy. The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s ...

ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce the creation of new educational resources for “Me + C3G,” its educational campaign for the rare ...

Newcastle researchers have revealed the first treatment to target the underlying cause of a rare kidney condition called "C3G" and prevent the disease progressing. Publishing in The Lancet, the ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this point ...

True or false: You can improve your C3 glomerulopathy symptoms and your kidney function with a high-sodium diet. National Kidney Foundation: “Complement 3 Glomerulopathy (C3G): Knowing the Signs and ...

DelveInsight's “Complement 3 Glomerulopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Complement 3 Glomerulopathy, historical and ...